Low-grade inflammation and tryptophan-kynurenine pathway activation are associated with adverse cardiac remodeling in primary hyperparathyroidism: the EPATH trial.
Verheyen N, Meinitzer A, Grübler MR, Ablasser K, Kolesnik E, Fahrleitner-Pammer A, Belyavskiy E, Trummer C, Schwetz V, Pieske-Kraigher E, Voelkl J, Alesutan I, Catena C, Sechi LA, Brussee H, Lewinski DV, März W, Pieske B, Pilz S, Tomaschitz A.
Verheyen N, et al. Among authors: meinitzer a.
Clin Chem Lab Med. 2017 Jun 27;55(7):1034-1042. doi: 10.1515/cclm-2016-1159.
Clin Chem Lab Med. 2017.
PMID: 28432842
Clinical Trial.